Baetke S C, Lammers T, Kiessling F
Department of Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany.
Br J Radiol. 2015 Oct;88(1054):20150207. doi: 10.1259/bjr.20150207. Epub 2015 Jun 12.
During the last decades, a plethora of nanoparticles have been developed and evaluated and a real hype has been created around their potential application as diagnostic and therapeutic agents. Despite their suggestion as potential diagnostic agents, only a single diagnostic nanoparticle formulation, namely iron oxide nanoparticles, has found its way into clinical routine so far. This fact is primarily due to difficulties in achieving appropriate pharmacokinetic properties and a reproducible synthesis of monodispersed nanoparticles. Furthermore, concerns exist about their biodegradation, elimination and toxicity. The majority of nanoparticle formulations that are currently routinely used in the clinic are used for therapeutic purposes. These therapeutic nanoparticles aim to more efficiently deliver a (chemo-) therapeutic drug to the pathological site, while avoiding its accumulation in healthy organs and tissues, and are predominantly based on the "enhanced permeability and retention" (EPR) effect. Furthermore, based on their ability to integrate diagnostic and therapeutic entities within a single nanoparticle formulation, nanoparticles hold great promise for theranostic purposes and are considered to be highly useful for personalizing nanomedicine-based treatments. In this review article, we present applications of diagnostic and therapeutic nanoparticles, summarize frequently used non-invasive imaging techniques and describe the role of EPR in the accumulation of nanotheranostic formulations. In this context, the clinical potential of nanotheranostics and image-guided drug delivery for individualized and improved (chemo-) therapeutic interventions is addressed.
在过去几十年中,人们开发并评估了大量的纳米颗粒,围绕其作为诊断和治疗剂的潜在应用引发了一场真正的热潮。尽管它们被认为是潜在的诊断剂,但到目前为止,只有一种诊断性纳米颗粒制剂,即氧化铁纳米颗粒,进入了临床常规应用。这一事实主要是由于难以实现合适的药代动力学性质以及难以可重复地合成单分散纳米颗粒。此外,人们还对它们的生物降解、消除和毒性存在担忧。目前临床上常规使用的大多数纳米颗粒制剂用于治疗目的。这些治疗性纳米颗粒旨在更有效地将(化学)治疗药物递送至病理部位,同时避免其在健康器官和组织中的蓄积,并且主要基于“增强的渗透和滞留”(EPR)效应。此外,基于纳米颗粒能够在单一纳米颗粒制剂中整合诊断和治疗实体的能力,纳米颗粒在诊疗一体化方面具有巨大潜力,并且被认为对基于纳米医学的个性化治疗非常有用。在这篇综述文章中,我们介绍了诊断性和治疗性纳米颗粒的应用,总结了常用的非侵入性成像技术,并描述了EPR在纳米诊疗制剂蓄积中的作用。在此背景下,探讨了纳米诊疗和图像引导药物递送在个体化和改进(化学)治疗干预方面的临床潜力。